Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Next Science - Potential Anti-Inflammatory Benefit For XPERIENCE (ASX:NXS)

Highlights: Dr Andrew B. Wickline, MD, FAAOS has released the findings of a pilot study which demonstrated 54% lower inflammation within 14 days compared to the common reference ...read more

Next Science - Investor Presentation (ASX:NXS)

To view the Investor Presentation, download the attached PDF.

Next Science - Investor Presentation - Q2 2023 (ASX:NXS)

To view the presentation, download the attached PDF.

Next Science - Appendix 4C - 30 June 2023 (ASX:NXS)

To view the appendix, download the attached PDF.

Next Science - Quarterly Activity Report - 30 June 2023 (ASX:NXS)

Highlights: -- 2QFY23 Product Sales (unaudited) increased 27% qoq and 71% yoy to US$5.6m -- Direct channel Product Sales increased 50% qoq and 258% yoy to US$4.3m -- 1HFY23 Unaudited Product Sa...read more

Next Science - Market Update (ASX:NXS)

Sydney Australia Thursday, 29 June 2023: Next Science Limited (ASX: NXS) (Next Science or Company), a medical technology company focused on commercialising its proprietary XBIOTM suite of products t...read more

Next Science - Appointment of new Managing Director and CEO (ASX:NXS)

Sydney Australia Friday, 16 June 2023: Next Science Limited (ASX: NXS) (Next Science or Company), a medical technology company focused on commercialising its proprietary XBIOTM suite of products to ...read more

Next Science - Quarterly Activity Report - 31 March 2023 (ASX:NXS)

Highlights: 1QFY23 Product Sales (unaudited) increased 46% qoq and 130% yoy to US$4.4m. Direct channel Product Sales increased 35% qoq and 188% yoy to US$2.9m. Wound Care presc...read more

Next Science - Appendix 4C - 31 March 2023 (ASX:NXS)

To view the appendix, download the attached PDF.

Next Science - FY22 Investor Presentation (ASX:NXS)

To view the presentation, download the attached PDF.

Next Science - FY22 Results and FY23 Outlook (ASX:NXS)

Highlights: Audited full-year product revenue of US$11.3m, reflecting a 40% increase on FY21.Total revenue of US$11.7m increased 31% yoy. Gross margin steady at 78%, with Gross ...read more

Next Science - Appendix 4E / FY22 Financial Statements (ASX:NXS)

To view the Appendix 4E / FY22 Financial Statements, download the attached PDF.

Next Science - Investor Presentation - Q4 2022 (ASX:NXS)

To view the presentation, download the attached PDF.

Next Science - Appendix 4C - 31 December 2022 (ASX:NXS)

To view the appendix, download the attached PDF.

Next Science - Quarterly Activity Report - 31 December 2022 (ASX:NXS)

Sydney, Australia, Monday, 30 January 2023: Next Science Limited (ASX:NXS) (Next Science/Company) today announced its Appendix 4C Quarterly Cash Flow Report for the period 1 October 2022 to 31 Decem...read more

Viewing: 16 - 30 of 200 Previous | Next